M M Berger1, O Appelberg2, A Reintam-Blaser3, C Ichai4, O Joannes-Boyau5, M Casaer6, S J Schaller7, J Gunst8, J Starkopf9. 1. Lausanne University Hospital, Lausanne, Switzerland. Electronic address: Mette.Berger@chuv.ch. 2. University of Tartu, Tartu University Hospital, Tartu, Estonia. Electronic address: oskar.appelberg@gmail.com. 3. Lucerne Cantonal Hospital, Dpt of Intensive Care Medicine, Lucerne, Switzerland. Electronic address: annika.reintam.blaser@ut.ee. 4. Université Côte d'Azur, Mixed Intensive Care Unit, Nice, France. Electronic address: ichai@unice.fr. 5. Centre hospitalier universitaire de Bordeaux, Bordeaux, France. Electronic address: olivier.joannes-boyau@chu-bordeaux.f. 6. Department of Intensive Care Medicine, University Hospital Leuven, Leuven, Belgium. Electronic address: michael.casaer@uzleuven.be. 7. Charité, Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, And Berlin Institute of Health, Dpt of Anesthesiology and Operative Intensive Care Medicine, Berlin, Germany. Electronic address: stefan.schaller@charite.de. 8. KU Leuven, Dpt of Cellular and Molecular Medicine, Clinical, Dpt and Laboratory of Intensive Care Medicine, Belgium, Leuven. Electronic address: jan.gunst@kuleuven.be. 9. University of Tartu, Tartu University Hospital, Estonia. Electronic address: Joel.Starkopf@kliinikum.ee.
Abstract
BACKGROUND & AIMS: Hypophosphatemia (HypoP) is associated with organ dysfunction and mortality. Despite its potential severe consequences, HypoP remains poorly characterized in terms of real prevalence and timing of onset. The primary objective was to determine the prevalence of HypoP defined as blood phosphate <0.8 and < 0.65 mmol/l on one particular day at international level. METHODS: One-day point prevalence survey conducted by the Section of Metabolism, Endocrinology and Nutrition (MEN) of the European Society of Intensive Care Medicine (ESICM) during week 11-2020. RESULTS: In total, 56 adult and 4 paediatric ICUs, from 22 countries participated: 41 ICUs were mixed medico surgical, the 19 others being cardiac, medical or surgical. Phosphate measurements were performed daily in 21 ICUs, and 1-3 times per week in 39 ICUs. On D-Day 909 patients (883 adults) were present and 668/883 (75.7%) had serum/plasma phosphate determined, revealing a HypoP in 103 (15.4%) patients aged 62 [18 to 85] years. Of those, 49 patients presented phosphate <0.65 mmol/l: cases of hypophosphatemia were detected at any time of patient's ICU stay. No HypoP was observed in children. A treatment protocol existed only in 41.1% of adult ICUs, independently of ICU type, or size. Only 41/98 of the HypoP patients (29/41 of patients with phosphate <0.65 mmol/l) were receiving phosphate. CONCLUSION: HypoP is present at least in 15.4% of ICU patients, and may occur at any time during the ICU stay. The absence of phosphate repletion protocols in 60% of participating ICUs is an unexpected finding, and confirms the necessity for the development of ICU phosphate protocols and guidelines. CLINICALTRIALS IDENTIFIER: NCT04201899.
BACKGROUND & AIMS:Hypophosphatemia (HypoP) is associated with organ dysfunction and mortality. Despite its potential severe consequences, HypoP remains poorly characterized in terms of real prevalence and timing of onset. The primary objective was to determine the prevalence of HypoP defined as blood phosphate <0.8 and < 0.65 mmol/l on one particular day at international level. METHODS: One-day point prevalence survey conducted by the Section of Metabolism, Endocrinology and Nutrition (MEN) of the European Society of Intensive Care Medicine (ESICM) during week 11-2020. RESULTS: In total, 56 adult and 4 paediatric ICUs, from 22 countries participated: 41 ICUs were mixed medico surgical, the 19 others being cardiac, medical or surgical. Phosphate measurements were performed daily in 21 ICUs, and 1-3 times per week in 39 ICUs. On D-Day 909 patients (883 adults) were present and 668/883 (75.7%) had serum/plasma phosphate determined, revealing a HypoP in 103 (15.4%) patients aged 62 [18 to 85] years. Of those, 49 patients presented phosphate <0.65 mmol/l: cases of hypophosphatemia were detected at any time of patient's ICU stay. No HypoP was observed in children. A treatment protocol existed only in 41.1% of adult ICUs, independently of ICU type, or size. Only 41/98 of the HypoP patients (29/41 of patients with phosphate <0.65 mmol/l) were receiving phosphate. CONCLUSION: HypoP is present at least in 15.4% of ICU patients, and may occur at any time during the ICU stay. The absence of phosphate repletion protocols in 60% of participating ICUs is an unexpected finding, and confirms the necessity for the development of ICU phosphate protocols and guidelines. CLINICALTRIALS IDENTIFIER: NCT04201899.
Authors: Hannah Wozniak; André Dos Santos Rocha; Tal Sarah Beckmann; Christophe Larpin; Niccolò Buetti; Hervé Quintard; Jérôme Pugin; Claudia Paula Heidegger Journal: J Clin Med Date: 2022-01-24 Impact factor: 4.241
Authors: Jean-Charles Preiser; Yaseen M Arabi; Mette M Berger; Michael Casaer; Stephen McClave; Juan C Montejo-González; Sandra Peake; Annika Reintam Blaser; Greet Van den Berghe; Arthur van Zanten; Jan Wernerman; Paul Wischmeyer Journal: Crit Care Date: 2021-12-14 Impact factor: 9.097
Authors: Charat Thongprayoon; Yeshwanter Radhakrishnan; Wisit Cheungpasitporn; Tananchai Petnak; Fawad Qureshi; Michael A Mao; Kianoush B Kashani Journal: Can J Kidney Health Dis Date: 2022-07-26
Authors: Hannah Wozniak; Tal Sarah Beckmann; Lorin Fröhlich; Tania Soccorsi; Christophe Le Terrier; Aude de Watteville; Jacques Schrenzel; Claudia-Paula Heidegger Journal: Crit Care Date: 2022-08-18 Impact factor: 19.334